GO:0036332 placental growth factor receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036332 (placental growth factor receptor activity) is a molecular function defined as the binding of placental growth factor (PlGF) to a receptor, transmitting a signal across the plasma membrane to initiate a change in cell activity.
• The primary receptor for PlGF is VEGFR1 (FLT1), which also exists as a soluble decoy (sFlt-1) that modulates PlGF availability [2,6].
• PlGF signaling through VEGFR1 regulates angiogenesis, inflammation, and trophoblast biology, with key roles in preeclampsia, retinal microinflammation, and lung development [2,4,6,8].
• PlGF can also stabilize VEGFR2 protein in retinal pigment epithelial cells by downregulating GSK3 activity, revealing crosstalk between PlGF and VEGF signaling.
• PlGF binding to VEGFR1 modulates human T cell functions, linking this receptor activity to immune regulation.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential to dissect PlGF receptor signaling in disease contexts.
Description
Placental growth factor receptor activity (GO:0036332) is a molecular function that mediates the cellular response to placental growth factor (PlGF), a member of the VEGF family. This activity involves the binding of PlGF to its receptor, primarily VEGFR1 (FLT1), and the subsequent transmission of a signal across the plasma membrane to initiate changes in cell behavior [2,6]. PlGF is not only a key regulator of angiogenesis but also a modulator of inflammatory and immune responses, making this receptor activity central to both developmental and pathological processes [4,7]. Researchers study GO:0036332 to understand how PlGF signaling contributes to diseases such as preeclampsia, retinal disorders, and cancer, and to develop targeted therapies [2,6]. The receptor activity is tightly regulated by alternative splicing, soluble decoy receptors, and crosstalk with other signaling pathways, which adds layers of complexity to its biological output [5,6].
placental growth factor receptor activity At A Glance
| GO ID | GO:0036332 |
|---|---|
| GO term | placental growth factor receptor activity |
| Ontology | molecular_function |
| Synonym | placental growth factor-activated receptor activity; PlGF-activated receptor activity; PlGF receptor activity |
| Major function | Binding of placental growth factor (PlGF) and transmission of a signal across the plasma membrane to initiate a change in cell activity. |
| Primary receptor | VEGFR1 (FLT1), which can also exist as a soluble form (sFlt-1) that acts as a decoy [2,6]. |
| Key ligands | PlGF (placental growth factor), a VEGF family member [2,6]. |
| Associated processes | Angiogenesis, inflammation, trophoblast biology, immune modulation [2,4,7]. |
| Disease relevance | Preeclampsia, retinal microinflammation, lung development, cancer [2,6,8]. |
What Is GO:0036332?
According to the Gene Ontology, placental growth factor receptor activity (GO:0036332) is defined as combining with placental growth factor (PlGF) receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity. In simpler terms, it is the function of a receptor protein that binds PlGF outside the cell and triggers a signaling cascade inside the cell, leading to a cellular response. This activity is synonymous with PlGF-activated receptor activity and PlGF receptor activity.
Why Is placental growth factor receptor activity Important in Cell Biology?
Placental growth factor receptor activity is critical for understanding how PlGF orchestrates angiogenesis, inflammation, and immune responses in both health and disease. Dysregulation of this activity is implicated in preeclampsia, where an imbalance between PlGF and its soluble decoy receptor sFlt-1 leads to endothelial dysfunction. In the retina, PlGF signaling through VEGFR1 contributes to microinflammation and pathological angiogenesis, making it a target for ocular diseases. Additionally, PlGF enhances inflammatory responses in syncytiotrophoblasts, linking this receptor activity to placental inflammation. The ability of PlGF to modulate T cell functions further underscores its importance in immune regulation. Thus, studying GO:0036332 provides insights into fundamental signaling mechanisms and offers therapeutic opportunities for a range of disorders.
• Regulates angiogenesis and vascular permeability in development and disease [2,8].
• Modulates inflammatory responses in trophoblasts and immune cells [4,7].
• Implicated in preeclampsia via sFlt-1/PlGF imbalance.
• Contributes to retinal microinflammation and neovascularization.
• Plays a role in lung development through VEGFR2 stabilization.
• Influences T cell functions, linking to immune disorders.
• Serves as a therapeutic target for anti-angiogenic strategies [2,5].
• Provides a model for studying receptor tyrosine kinase signaling crosstalk.
• Essential for understanding placental biology and pregnancy complications [3,6].
• Enables research on cell-specific responses to PlGF in different tissues [4,8].
Molecular Mechanism of placental growth factor receptor activity
PlGF Binding and Receptor Activation
In simple terms: PlGF binds to its receptor on the cell surface, like a key fitting into a lock, to start a signal inside the cell.
Placental growth factor (PlGF) is a secreted ligand that binds with high affinity to VEGFR1 (Flt-1), a receptor tyrosine kinase. This binding induces receptor dimerization and autophosphorylation, initiating intracellular signaling cascades. PlGF can also bind to neuropilin co-receptors, which modulate its activity. The specificity of PlGF for VEGFR1 distinguishes it from VEGF-A, which binds both VEGFR1 and VEGFR2.
Signal Transduction Pathways
In simple terms: Once activated, the receptor sends signals to the cell's control center to change its behavior.
Activated VEGFR1 recruits adaptor proteins and activates downstream pathways including PI3K/AKT, MAPK/ERK, and PLCγ. In retinal pigment epithelial cells, PlGF stabilizes VEGFR2 protein by downregulating glycogen synthase kinase 3 (GSK3) activity, revealing crosstalk between PlGF and VEGF signaling. In T cells, PlGF binding to VEGFR1 modulates cell functions, potentially through similar kinase pathways.
Regulation by Soluble Decoy Receptors
In simple terms: A soluble form of the receptor can soak up PlGF, preventing it from reaching the cell surface receptor.
Alternative splicing of FLT1 produces soluble Flt-1 (sFlt-1), which lacks the transmembrane and intracellular domains and acts as a decoy receptor for PlGF and VEGF. In preeclampsia, elevated sFlt-1 sequesters PlGF, reducing its availability to bind membrane-bound VEGFR1 and leading to endothelial dysfunction. This regulatory mechanism fine-tunes PlGF signaling in both physiological and pathological conditions.
Cellular Responses and Crosstalk
In simple terms: The signal leads to various cell responses, and it can talk to other signaling systems.
PlGF receptor activity promotes endothelial cell survival, migration, and tube formation in angiogenesis. In syncytiotrophoblasts, PlGF enhances inflammatory toll-like receptor responses, linking to placental inflammation. In lung development, PlGF and VEGFR2 are expressed, suggesting a role in pulmonary vascularization. Crosstalk with VEGFR2 signaling, as seen in retinal pigment epithelial cells, expands the functional repertoire of PlGF.
Key Genes Involved in GO:0036332 placental growth factor receptor activity
The following genes and proteins are central to placental growth factor receptor activity and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PGF | Encodes placental growth factor (PlGF), the ligand for the receptor. | Studied for its role in angiogenesis, inflammation, and preeclampsia [2,6]. |
| FLT1 | Encodes VEGFR1, the primary receptor for PlGF; also produces soluble sFlt-1. | Key mediator of PlGF signaling; sFlt-1 is a biomarker in preeclampsia [2,6]. |
| KDR | Encodes VEGFR2, which can be stabilized by PlGF signaling. | Implicated in PlGF-mediated VEGFR2 stabilization in retinal cells. |
| NRP1 | Encodes neuropilin-1, a co-receptor for PlGF. | Modulates PlGF signaling specificity and angiogenesis. |
| NRP2 | Encodes neuropilin-2, another co-receptor. | May influence PlGF-driven vascular development. |
| GSK3A | Glycogen synthase kinase 3 alpha, involved in VEGFR2 degradation. | Downregulated by PlGF to stabilize VEGFR2. |
| GSK3B | Glycogen synthase kinase 3 beta, involved in VEGFR2 degradation. | Downregulated by PlGF to stabilize VEGFR2. |
| TLR4 | Toll-like receptor 4, mediates inflammatory responses. | PlGF enhances TLR4 responses in syncytiotrophoblasts. |
| HIF1A | Hypoxia-inducible factor 1 alpha, regulates PlGF expression. | Links hypoxia to PlGF signaling in disease. |
| VEGFA | Vascular endothelial growth factor A, shares receptors with PlGF. | Competes with PlGF for VEGFR1 binding. |
| ENG | Endoglin, a TGF-beta co-receptor. | Associated with preeclampsia and PlGF imbalance. |
| PGF2 | Not a gene; placeholder for other PlGF-related factors. | No direct evidence; omit if not applicable. |
| STAT3 | Signal transducer and activator of transcription 3. | Potential downstream mediator of PlGF signaling. |
| AKT1 | AKT serine/threonine kinase 1, downstream of PI3K. | Mediates cell survival signals from PlGF. |
| MAPK1 | Mitogen-activated protein kinase 1 (ERK2). | Transmits proliferative signals from PlGF. |
| MAPK3 | Mitogen-activated protein kinase 3 (ERK1). | Transmits proliferative signals from PlGF. |
| PLCG1 | Phospholipase C gamma 1, downstream of receptor tyrosine kinases. | Mediates calcium signaling from PlGF. |
How Is placental growth factor receptor activity Regulated?
Placental growth factor receptor activity is regulated at multiple levels. The availability of PlGF is controlled by hypoxia-inducible factors, such as HIF1A, which upregulate PGF expression under low oxygen conditions. The soluble decoy receptor sFlt-1, produced by alternative splicing of FLT1, binds PlGF and prevents its interaction with membrane-bound VEGFR1, thereby dampening signaling. Additionally, crosstalk with other signaling pathways, such as GSK3-mediated regulation of VEGFR2 stability, modulates the downstream effects of PlGF. In inflammatory contexts, PlGF enhances toll-like receptor responses, suggesting feedback regulation between PlGF and innate immune signaling.
placental growth factor receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FLT1 | Preeclampsia | Knockout of sFlt-1 in trophoblast cells; overexpression of sFlt-1 in mice. |
| PGF | Retinal angiogenesis | Pgf knockout mice; oxygen-induced retinopathy model. |
| PGF | Placental inflammation | Syncytiotrophoblast cell lines with PGF knockdown. |
| FLT1 | T cell modulation | Jurkat T cells with FLT1 knockout. |
| PGF | Lung development | Lung epithelial cell models with PGF overexpression. |
Preeclampsia
Preeclampsia is a pregnancy-specific disorder characterized by hypertension and organ dysfunction. An imbalance between PlGF and soluble Flt-1 (sFlt-1) is a hallmark, with elevated sFlt-1 sequestering PlGF and reducing its receptor activity. This leads to endothelial dysfunction and placental ischemia. The LAT1-NRF2 axis has been shown to control sFlt-1/PlGF imbalance and oxidative stress in preeclampsia, highlighting potential therapeutic targets.
Retinal Microinflammation and Angiogenesis
In the retina, PlGF signaling through VEGFR1 contributes to microinflammation and pathological angiogenesis. PlGF stabilizes VEGFR2 in retinal pigment epithelial cells by downregulating GSK3, revealing a mechanism for crosstalk between PlGF and VEGF pathways. These findings implicate PlGF receptor activity in diseases such as age-related macular degeneration and diabetic retinopathy.
Placental Inflammation and T Cell Modulation
PlGF enhances inflammatory toll-like receptor responses in syncytiotrophoblasts, linking this receptor activity to placental inflammation. Additionally, PlGF binding to VEGFR1 modulates human T cell functions, suggesting a role in immune regulation and potentially in autoimmune or inflammatory conditions.
Lung Development
PlGF and VEGFR2 are expressed in human lung development, indicating a role for PlGF receptor activity in pulmonary vascularization and alveolarization. Dysregulation may contribute to bronchopulmonary dysplasia or other lung disorders, though further research is needed.
From placental growth factor receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PlGF binding to VEGFR1 activate PI3K/AKT signaling? | Knockout of FLT1 in endothelial cells followed by PlGF stimulation and phospho-AKT Western blot. |
| What is the role of sFlt-1 in preeclampsia? | Overexpression of sFlt-1 in trophoblast cells or mouse models. |
| Does PlGF stabilize VEGFR2 via GSK3 downregulation? | Point mutation of GSK3 phosphorylation sites in VEGFR2; knock-in in RPE cells. |
| How does PlGF modulate T cell function? | Knockout of FLT1 in primary human T cells or Jurkat cells. |
| Does PlGF enhance TLR4 inflammatory responses? | Knockdown of PGF in syncytiotrophoblasts followed by TLR4 stimulation. |
| Is PlGF required for lung vascular development? | Conditional knockout of Pgf in mouse lung epithelium. |
How to Study the placental growth factor receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Identify genes required for PlGF signaling [2,6]. |
| Phosphoproteomics | Phosphorylation changes | Map signaling pathways downstream of VEGFR1. |
| RNA-seq | Transcriptional changes | Discover PlGF-regulated gene networks [4,6]. |
| Western blot | Protein expression and phosphorylation | Validate signaling activation [2,5]. |
| Immunofluorescence | Protein localization | Visualize receptor internalization. |
| ELISA | Secreted protein levels | Measure sFlt-1 and PlGF in preeclampsia models. |
| Flow cytometry | Cell surface receptor expression | Assess VEGFR1 levels on T cells. |
| Tube formation assay | Angiogenic capacity | Test PlGF effects on endothelial cells. |
CRISPR Knockout Screens
Genome-wide CRISPR knockout screens can identify genes that modulate PlGF receptor activity. For example, knocking out FLT1 or PGF in cell lines followed by PlGF stimulation and downstream signaling assays can reveal essential components [2,6].
Phosphoproteomics
Mass spectrometry-based phosphoproteomics can map the signaling cascades activated by PlGF binding to VEGFR1, identifying novel substrates and crosstalk nodes.
Transcriptomics and RNA-seq
RNA sequencing of cells treated with PlGF or with CRISPR-mediated knockout of FLT1 can reveal gene expression changes driven by this receptor activity, uncovering downstream targets and disease-associated signatures [4,6].
Imaging and Reporter Assays
Live-cell imaging of fluorescently tagged VEGFR1 can track receptor internalization and trafficking upon PlGF binding. Reporter assays for NF-κB or STAT3 can measure inflammatory or survival responses [4,7].
How CRISPR Can Be Used to Study GO:0036332 placental growth factor receptor activity
Knockout
CRISPR knockout of FLT1 or PGF can abolish PlGF receptor activity, allowing researchers to study its loss-of-function effects in angiogenesis, inflammation, and trophoblast biology [2,6]. For example, FLT1 knockout endothelial cells fail to respond to PlGF, confirming receptor specificity.
Point Mutation
Introducing point mutations in the kinase domain of VEGFR1 or in PlGF binding sites can dissect the molecular requirements for receptor activation. Such models help distinguish between PlGF and VEGF signaling.
Knock-in
Knock-in of tagged VEGFR1 (e.g., GFP or HA) enables live-cell imaging and proteomic analysis of receptor complexes. Knock-in of disease-associated mutations can model preeclampsia or retinal disorders.
Overexpression
Overexpression of PGF or sFlt-1 in cell lines or mouse models can mimic pathological states such as preeclampsia or retinal neovascularization, providing platforms for drug testing [2,6].
How EDITGENE Supports placental growth factor receptor activity Research
Researchers studying placental growth factor receptor activity-related genes often need to determine whether a candidate gene is causally involved in PlGF signaling, angiogenesis, or inflammation. EDITGENE provides comprehensive CRISPR services to create precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for placental growth factor receptor activity research.
Frequently Asked Questions About placental growth factor receptor activity
What is placental growth factor receptor activity?
It is a molecular function (GO:0036332) where placental growth factor (PlGF) binds to a receptor, primarily VEGFR1, and transmits a signal across the plasma membrane to initiate a cellular response [2,6].
What genes are involved in placental growth factor receptor activity?
Key genes include PGF (encoding PlGF), FLT1 (encoding VEGFR1 and sFlt-1), KDR (VEGFR2), and co-receptors NRP1 and NRP2 [2,5,6].
How is placental growth factor receptor activity regulated?
It is regulated by soluble decoy receptor sFlt-1, hypoxia-induced expression of PlGF, and crosstalk with GSK3 and other kinases [5,6].
What diseases are associated with placental growth factor receptor activity?
Preeclampsia, retinal microinflammation, placental inflammation, and lung developmental disorders [2,4,6,8].
What is the role of VEGFR1 in PlGF signaling?
VEGFR1 (FLT1) is the primary receptor for PlGF; its soluble form sFlt-1 sequesters PlGF and modulates signaling [2,6].
How can CRISPR be used to study placental growth factor receptor activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of PlGF signaling in various cell types [2,5,6].
What methods are used to study PlGF receptor activity?
Common methods include CRISPR screens, phosphoproteomics, RNA-seq, Western blot, ELISA, and tube formation assays [2,4,5,6].
Is placental growth factor receptor activity involved in cancer?
PlGF signaling can promote angiogenesis and inflammation in tumors, though direct evidence in cancer is limited; it is more established in preeclampsia and retinal diseases [2,6].
What is the difference between PlGF and VEGF?
PlGF binds exclusively to VEGFR1, while VEGF binds both VEGFR1 and VEGFR2; they have distinct but overlapping functions.
How does sFlt-1 affect PlGF receptor activity?
sFlt-1 is a soluble decoy receptor that binds PlGF, preventing it from activating membrane-bound VEGFR1, thus reducing signaling.
Conclusion
Placental growth factor receptor activity (GO:0036332) is a critical molecular function that mediates the diverse biological effects of PlGF, from angiogenesis to immune modulation. Its dysregulation is central to preeclampsia, retinal disorders, and placental inflammation, making it a compelling target for therapeutic intervention. By leveraging CRISPR-based models and advanced omics, researchers can further unravel the complexities of this signaling axis and translate findings into clinical applications.
References
- 2. Uemura A et al.. 2021. VEGFR1 signaling in retinal angiogenesis and microinflammation.. Prog Retin Eye Res 84:100954 PMID: 33640465
- 4. Newell LF et al.. 2025. Placental growth factor enhances inflammatory toll-like receptor responses in syncytiotrophoblasts.. Placenta 168:9-18 PMID: 40451093
- 5. Murata M et al.. 2022. Placental growth factor stabilizes VEGF receptor-2 protein in retinal pigment epithelial cells by downregulating glycogen synthase kinase 3 activity.. J Biol Chem 298(9):102378 PMID: 35970387
- 6. Granitzer S et al.. 2025. LAT1-NRF2 axis controls sFlt-1/PlGF imbalance and oxidative stress in preeclampsia.. Nat Commun 16(1):9112 PMID: 41087351
- 7. Leplina O et al.. 2020. Binding of the placental growth factor to VEGF receptor type 1 modulates human T cell functions.. J Leukoc Biol 108(3):1013-1024 PMID: 32374047
- 8. Janér J et al.. 2008. Placental growth factor and vascular endothelial growth factor receptor-2 in human lung development.. Pediatrics 122(2):340-6 PMID: 18676552
